| Platinum-Sensitive Malignant Female Reproductive System Neoplasm studied in …STUDIED_INderived10 of 26show all (up to 200) |
|---|
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225270Phase 3 · recruiting Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07564141Phase 3 · recruiting Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776171Phase 2 · not yet recruiting Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04550494Phase 2 · active not recruiting Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05579366Phase 1/Phase 2 · recruiting Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627443Phase 1 · active not recruiting Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |